Indivior Pharmaceuticals, Inc. Accumulated Other Comprehensive Income
Indivior Pharmaceuticals, Inc. (SUPN) had Accumulated Other Comprehensive Income of -$28.00 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-03
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$28.00M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$29.00M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$30.00M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$32.00M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$28.00M 10-Q · filed 2026-08-03 |
| 2026-03-31 | -$29.00M 10-Q · filed 2026-04-30 |
| 2025-12-31 | -$30.00M 10-Q · filed 2026-08-03 |
| 2025-09-30 | -$32.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | -$33.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | -$35.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | -$36.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$30.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |